Advances in the role of Dickkopf (DKK1) in myeloma bone disease and its targeted therapy
10.3781/j.issn.1000-7431.2011.03.017
- Author:
Shan MENG
1
Author Information
1. Department of Hematology
- Publication Type:Journal Article
- Keywords:
Antineoplastic protocols;
Glycoproteins;
Multiple myeloma;
Myeloma bone disease
- From:
Tumor
2011;31(3):273-276
- CountryChina
- Language:Chinese
-
Abstract:
Myeloma bone disease (MBD) with the characteristic of progressing osteolysis, is one of the main clinical manifestations of multiple myeloma (MM). In recent years, it was revealed that a kind of glycoprotein - Dickkopf (DKK1) associated with embryonic development and tumor progression can inhibit the Wnt signal pathway. The DKK1 efficacy in inhibiting the steoblasts and activating the osteoclasts appears to play an important role in MBD. The ongoing MBD-targeting therapies involving DKK1 neutralizing antibody, proteasome inhibitor, vaccine and regulatory factor on the basis of this mechanism have shown some benefit for MBD. Copyright© 2011 by the Editorial Board of Tumor.
